Details of Disease

General Information of Disease (ID: DISLGVL7)

• Disease Name: Choroidal neovascularization
• Disease Class: 9B76: Degenerative high myopia
• Definition: An eye disorder described by the growth of new blood vessels that originate from the choroid through a break in the Bruch membrane into the subretinal pigment epithelium (sub-RPE) or subretinal space. Choroidal neovascularization (CNV) is a major cause of visual loss.
• Disease Hierarchy:
  DISB52BH: Eye disorder
  DISLGVL7: Choroidal neovascularization
• ICD Code:
  ICD-11: ICD-11: 9B76
  ICD-10: ICD-10: H35
  ICD-9: ICD-9: 362.5
  Expand ICD-11: 9B78.3
  Expand ICD-10: H35
  Expand ICD-9: 362.5
• Disease Identifiers:
  MONDO ID: MONDO_0810000
  MESH ID: D020256
  UMLS CUI: C0600518
  MedGen ID: 154726
  HPO ID: HP:0011506

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 2 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Imatinib	DM7RJXL	Approved	Small molecular drug	[1]
Verteporfin	DMIY6DB	Approved	Small molecular drug	[2]

This Disease is Treated as An Indication in 2 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
RG7716	DMKDHU2	Phase 3	Small molecular drug	[3]
Dexamethasone palmitate	DMCMT4V	Phase 1/2	Small molecular drug	[4]

This Disease is Treated as An Indication in 1 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AGN211745	DMZRW5E	Discontinued in Phase 2	siRNA drug	[5]

This Disease is Treated as An Indication in 1 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
SRPIN-340	DMISKJ9	Investigative	Small molecular drug	[6]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 14 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ADIPOQ	TTXKA7D	Strong	Therapeutic	[7]
AOC3	TT7HC21	Strong	Biomarker	[8]
CFH	TTUW6OP	Strong	Genetic Variation	[9]
FGF2	TTGKIED	Strong	Therapeutic	[10]
FLT1	TT1VAUK	Strong	Therapeutic	[11]
HGF	TT4V2JM	Strong	Biomarker	[12]
HTRA1	TT8POQR	Strong	Genetic Variation	[9]
ICAM1	TTA1L39	Strong	Biomarker	[13]
ITGAV	TTT1R2L	Strong	Biomarker	[14]
KDR	TTUTJGQ	Strong	Therapeutic	[15]
LEP	TTBJEZ5	Strong	Biomarker	[16]
SERPINF1	TTR59S1	Strong	Biomarker	[17]
TYMP	TTO0IB8	Strong	Biomarker	[18]
VEGFA	TT3LJ9K	Strong	Biomarker	[12]

This Disease Is Related to 3 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ARMS2	OTUXHJ9H	Strong	Genetic Variation	[19]
PROK1	OT8S7RUG	Strong	Altered Expression	[20]
PRPH2	OTNH2G5H	Strong	Genetic Variation	[21]

References

• [1] Imatinib FDA Label
• [2] Verteporfin FDA Label
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8529).
• [4] Clinical pipeline report, company report or official report of Santen Pharmaceutical.
• [5] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019725)
• [6] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [7] Inhibitory role of adiponectin peptide I on rat choroidal neovascularization.Biochim Biophys Acta. 2012 Aug;1823(8):1264-72. doi: 10.1016/j.bbamcr.2012.05.017. Epub 2012 May 23.
• [8] Vascular adhesion protein-1 blockade suppresses choroidal neovascularization.FASEB J. 2008 Aug;22(8):2928-35. doi: 10.1096/fj.07-105346. Epub 2008 Apr 24.
• [9] Genotype-phenotype correlations for exudative age-related macular degeneration associated with homozygous HTRA1 and CFH genotypes.Invest Ophthalmol Vis Sci. 2008 Jul;49(7):3090-4. doi: 10.1167/iovs.07-1540. Epub 2008 Mar 24.
• [10] Inhibitory effect of TNP-470 on experimental choroidal neovascularization in a rat model.Invest Ophthalmol Vis Sci. 1999 Jun;40(7):1512-9.
• [11] Long-term efficacy of ciliary muscle gene transfer of three sFlt-1 variants in a rat model of laser-induced choroidal neovascularization.Gene Ther. 2013 Nov;20(11):1093-103. doi: 10.1038/gt.2013.36. Epub 2013 Jun 27.
• [12] Differences in the temporal expression of regulatory growth factors during choroidal neovascular development.Exp Eye Res. 2009 Jan;88(1):79-91. doi: 10.1016/j.exer.2008.10.014. Epub 2008 Nov 1.
• [13] Effect of sorafenib on experimental choroidal neovascularization in the rat.Clin Exp Ophthalmol. 2010 Oct;38(7):718-26. doi: 10.1111/j.1442-9071.2010.02328.x. Epub 2010 Jul 9.
• [14] Inhibition of experimental choroidal neovascularization in rats by an alpha(v)-integrin antagonist.Curr Eye Res. 2004 May;28(5):359-66. doi: 10.1076/ceyr.28.5.359.28678.
• [15] Selective photodynamic therapy by targeted verteporfin delivery to experimental choroidal neovascularization mediated by a homing peptide to vascular endothelial growth factor receptor-2.Arch Ophthalmol. 2004 Jul;122(7):1002-11. doi: 10.1001/archopht.122.7.1002.
• [16] Metabolic syndrome triggered by high-fructose diet favors choroidal neovascularization and impairs retinal light sensitivity in the rat.PLoS One. 2014 Nov 7;9(11):e112450. doi: 10.1371/journal.pone.0112450. eCollection 2014.
• [17] [Expression and signification of pigment epithelium-derived factor in experimental choroidal neovascularization of rat].Zhonghua Yan Ke Za Zhi. 2004 Jun;40(6):404-8.
• [18] Subconjunctival doxifluridine administration suppresses rat choroidal neovascularization through activated thymidine phosphorylase.Invest Ophthalmol Vis Sci. 2003 Feb;44(2):751-4. doi: 10.1167/iovs.02-0222.
• [19] Myopic choroidal neovascularization genetics.Ophthalmology. 2008 Sep;115(9):1632, 1632.e1. doi: 10.1016/j.ophtha.2008.03.004.
• [20] Choroidal neovascularization in transgenic mice expressing prokineticin 1: an animal model for age-related macular degeneration.Mol Ther. 2006 Mar;13(3):609-16. doi: 10.1016/j.ymthe.2005.08.024. Epub 2005 Nov 2.
• [21] Choroidal neovascularization in patients with adult-onset foveomacular dystrophy caused by mutations in the RDS/peripherin gene.Adv Exp Med Biol. 2006;572:35-40. doi: 10.1007/0-387-32442-9_6.